This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Serotonergic psychedelic: Difference between revisions
>ExistingEntity Alphabetization |
>Unity Expanded lit. section. |
||
| Line 193: | Line 193: | ||
===Overview=== | ===Overview=== | ||
* Nichols, D. E. (2016). '''''Psychedelics.''''' Pharmacological reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478 | * Nichols, D. E. (2016). '''''Psychedelics.''''' Pharmacological reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478 | ||
* Johansen, P. Ø., & Krebs, T. S. (2015). '''''Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology''''', 29(3), 270-279. https://doi.org/10.1177/0269881114568039 | |||
* Geyer, M. A., Nichols, D. E., & Vollenweider, F. X. (2009). '''''Serotonin-related psychedelic drugs.''''' https://doi.org/10.1016/b978-008045046-9.01160-8 | * Geyer, M. A., Nichols, D. E., & Vollenweider, F. X. (2009). '''''Serotonin-related psychedelic drugs.''''' https://doi.org/10.1016/b978-008045046-9.01160-8 | ||
* Nichols, C. D., & Sanders-Bush, E. (2001). '''''Serotonin receptor signaling and hallucinogenic drug action'''''. Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf | * Nichols, C. D., & Sanders-Bush, E. (2001). '''''Serotonin receptor signaling and hallucinogenic drug action'''''. Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf | ||
* Halberstadt, A. L. (2015). '''''Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.''''' Behavioral Brain Research, 277, 99–120. https://doi.org/10.1016/j.bbr.2014.07.016 | * Halberstadt, A. L. (2015). '''''Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.''''' Behavioral Brain Research, 277, 99–120. https://doi.org/10.1016/j.bbr.2014.07.016 | ||
* Béïque, J. C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007). '''''Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex.''''' Proceedings of the National Academy of Sciences, 104(23), 9870-9875. | |||
* Winter, J. C., Fiorella, D. J., Timineri, D. M., Filipink, R. A., Helsley, S. E., & Rabin, R. A. (1999). '''''Serotonergic receptor subtypes and hallucinogen-induced stimulus control'''''. Pharmacology Biochemistry and Behavior, 64(2), 283-293. http://doi.org/10.1016/S0091-3057(99)00063-5. | * Winter, J. C., Fiorella, D. J., Timineri, D. M., Filipink, R. A., Helsley, S. E., & Rabin, R. A. (1999). '''''Serotonergic receptor subtypes and hallucinogen-induced stimulus control'''''. Pharmacology Biochemistry and Behavior, 64(2), 283-293. http://doi.org/10.1016/S0091-3057(99)00063-5. | ||
* Nichols, D. E. (2004). '''''Hallucinogens.''''' Pharmacology & therapeutics, 101(2), 131-181. | * Nichols, D. E. (2004). '''''Hallucinogens.''''' Pharmacology & therapeutics, 101(2), 131-181. | ||
* Vollenweider, F. X., & Kometer, M. (2010). '''''The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.''''' Nature Publishing Group, 11(9), 642–651. https://doi.org/10.1038/nrn2884 | |||
===Specific Examples=== | ===Specific Examples=== | ||
* Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). '''''The Pharmacology of Lysergic Acid Diethylamide: A Review''''', 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x | * Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). '''''The Pharmacology of Lysergic Acid Diethylamide: A Review''''', 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x | ||